BioSpace News Archive

Largest bi-coastal vivarium services provider in U.S. opens sixth coworking space

Dyve Biosciences, Inc. announced that longtime Pfizer Executive Chuck Harbert, Ph.D. has joined the company in the role of Chief Scientific Officer.

Biotech Showcase™ 2020 Conference on Monday, January 13th, 2020 at 11:30 a.m. PST in San Francisco, CA.

Replimune Group Inc. (NASDAQ: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, today announced that Robert Coffin, Ph.D., Chief Executive Officer and Director of Replimune, will present at the 38th Annual J.P.Morgan Healthcare Conference

Paragon Genomics, Inc., a leader in amplicon-based target enrichment solutions for next-generation sequencing (NGS) and precision medicine, today announced that it will present at Biotech Showcase™ 2020, to be held January 13–15, 2020 at the Hilton San Francisco Union Square. Paragon Genomics CEO Tao Chen will give a corporate presentation and meet with investors.

Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that it has entered into an option and license agreement to acquire exclusive, worldwide rights from ImmuNext Inc. (ImmuNext) to develop and commercialize anti-VISTA antibodies for the treatment of cancer, including ImmuNext’s lead compound, CI-8993 (formerly JNJ-61610588)

AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced the successful completion of patient enrollment in the aMAZE™ clinical trial.

Beta Lifescience, a world leading biotech company based in NJ, USA, announces that scientists in the field of cancer immunotherapy, immune checkpoint, targeted therapy, etc. now have access to the quality immune checkpoint protein products through the company’s newly launched website.

Aura Biosciences, a clinical-stage biopharmaceutical company developing a new class of tumor targeted therapies for initial application in primary tumors such as ocular and bladder cancers, today announced the appointment of George Golumbeski, Ph.D., as Chairman of its Board of Directors.

ImmunityBio, a privately held immunotherapy company focused on developing a T-cell memory cancer vaccine, today announced that Patrick Soon-Shiong, M.D., Chairman and Chief Executive Officer, will present at the 38th Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2020